Advertisements

Jatenzo

Quick links to important sections

Jatenzo

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Jatenzo

Property Description
Active ingredient Testosterone undecanoate
Form Liquid-filled oral capsule
Pharmacological class Androgen and Anabolic Steroid (AAS)
Common use Testosterone Replacement Therapy (TRT)
Origin Synthetic ester prodrug

Jatenzo: Definition and Pharmacological Class

Jatenzo is a prescription-only medication classified as an androgen. Its active ingredient is testosterone undecanoate, which is a synthetic ester prodrug derived from the naturally occurring hormone testosterone. The drug functions as an androgen receptor agonist, providing necessary hormonal substitution. Due to its potent hormonal activity, it is categorized as an Anabolic Steroid and a controlled substance (CIII).

Active Composition and Unique Oral Formulation

The medication is supplied distinctly as a liquid-filled oral capsule. The testosterone undecanoate is dissolved in a specialized oil-based vehicle that includes oleic acid and borage seed oil. This unique composition is crucial because it facilitates the drug's absorption primarily through the intestinal lymphatic system. This delivery method is engineered to minimize the extensive first-pass metabolism in the liver, which would otherwise inactivate other forms of orally ingested testosterone. This makes Jatenzo a clinically recognized oral alternative for testosterone delivery.

Purpose in Testosterone Replacement Therapy (TRT)

The general therapeutic function of Jatenzo is to provide Testosterone Replacement Therapy (TRT) for adult males. The medication is indicated for treating conditions involving a proven deficiency or absence of endogenous testosterone, such as specific types of hypogonadism. By restoring circulating testosterone to a normal physiological range, the medication helps correct the core hormonal imbalance associated with the documented deficiency. This use scenario typically involves patients seeking a consistent, non-injectable method for hormone maintenance.

Advertisements

What side effects are possible with Jatenzo?

Official Safety Classification and Serious Risks

The U.S. Food and Drug Administration (FDA) classifies Jatenzo with a Boxed Warning regarding the risk of increases in blood pressure. This elevation in blood pressure has the potential to increase the risk of Major Adverse Cardiovascular Events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death. Other serious reactions documented in the official labeling include Venous Thromboembolism (VTE), such as deep vein thrombosis and pulmonary embolism, as well as the potential for hepatic adverse effects and an increased risk of prostate cancer. The risk of Depression and Suicidal Ideation has also been reported in clinical trials.


Common Adverse Reactions and Organ System Effects

Based on clinical trial data, the most common adverse reactions are those occurring in two percent (2%) or more of patients. These effects are generally grouped into disorders of the blood, vasculature, and gastrointestinal systems.

  • Blood and Lymphatic System Disorders are commonly associated with polycythemia (increased red blood cell mass) and increased hematocrit.
  • Vascular Disorders include frequent reports of hypertension and headache.
  • Gastrointestinal Disorders that are common include diarrhea, dyspepsia (indigestion), eructation (burping), and nausea.
  • Other common effects involve prostatomegaly (enlarged prostate), gynecomastia (breast enlargement), peripheral edema (swelling), and decreased High-Density Lipoprotein (HDL) cholesterol.

Population and Contextual Safety Characteristics

Safety notes for specific patient groups are addressed in official documentation. The risk of edema (swelling) is noted as a concern for patients with pre-existing cardiac, renal, or hepatic disease. The medication is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate. It is not approved for use in women, particularly those who are pregnant, due to the potential for fetal harm.

Advertisements

Overdose and Emergency Response

The official regulatory documentation links overexposure to testosterone undecanoate to serious adverse outcomes, primarily when the medication is misused at doses higher than those recommended. Overdose manifestations include severe psychiatric and central nervous system effects such as mania, paranoia, psychosis, aggression, convulsions, and major depression. Physical signs of overexposure may also include priapism (long-lasting erections) and unexplained weight gain.

High-dose exposure is associated with life-threatening systemic outcomes. These include major cardiovascular events such as cardiac arrest, myocardial infarction (heart attack), and cerebrovascular accident (stroke). Hepatotoxicity (severe liver problems) is also cited as a risk. Overexposure can pose a specific risk of severe fluid retention leading to congestive heart failure in individuals with pre-existing cardiac, renal, or hepatic disease.

In the event of suspected overexposure, the regulatory procedure mandates immediate discontinuation of the drug. Patients must seek emergency medical attention for any signs of a major cardiovascular event (e.g., chest pain, slurred speech) or symptoms indicating acute liver damage (e.g., yellowing skin, dark urine). Management consists solely of appropriate symptomatic and supportive care, as no specific antidote is known. Monitoring involves checking serum testosterone concentration and hematocrit levels.

Advertisements

Therapeutic Uses of Jatenzo

What Jatenzo Treats: Main Uses and Benefits

Jatenzo is considered relevant for Testosterone Replacement Therapy (TRT) in adult males who have a documented deficiency or absence of natural testosterone. This replacement is indicated for specific forms of male hypogonadism that stem from identifiable structural or genetic causes, such as testicular failure, Klinefelter syndrome, or pituitary-hypothalamic injury. The primary therapeutic purpose is relevant for easing systemic imbalance by helping to sustain serum testosterone within a desired range for chronic management.

The medication is applied in addressing symptom clusters that may become disruptive due to low testosterone levels. This may assist with easing symptoms that interfere with daily functioning, such as deficits in sexual function (decreased libido and erectile difficulties). Furthermore, the therapy is generally used to ease systemic symptoms such as chronic fatigue, persistent low energy levels, and adverse mood changes.

The treatment supports symptoms related to physical discomfort, specifically those concerning lean muscle mass and muscle strength, and is relevant for easing the impact of deficiency on bone mineral density.

This support assists with maintaining functional stability and contributes to general well-being during symptomatic phases.


Quick Fact: Relief for Systemic Fatigue The therapy supports the patient during episodes of low energy by addressing the hormonal deficit that is often the underlying cause of chronic fatigue in hypogonadal men.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The medication is officially indicated for adult males with a documented deficiency or absence of testosterone due to specific structural or genetic etiologies, such as testicular failure or pituitary injury. Use is strictly limited to this population.

Jatenzo is contraindicated (must not be used) in several absolute situations, including men with carcinoma of the breast or known or suspected carcinoma of the prostate, and women who are pregnant (due to the risk of fetal harm). It is also contraindicated for men with a known hypersensitivity to any of its ingredients.

Population Eligibility Status Official Regulatory Finding
Use Not Established Males under 18 years of age (safety and efficacy have not been established). Men with "age-related hypogonadism" (efficacy not established for this non-etiological condition).
Not Recommended for Use Men with uncontrolled hypertension.
Conditional Use Required Patients with pre-existing cardiac, renal, or hepatic disease (due to regulatory caution regarding fluid retention).

The official labeling notes insufficient long-term safety data in the geriatric population to fully assess potential risks.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Jatenzo (testosterone undecanoate) can interact with certain other medications, potentially requiring dose adjustments or careful monitoring by a healthcare provider. It is important to inform your doctor about all prescription and over-the-counter drugs, vitamins, and herbal supplements you are taking.

Key drug interactions include:

  • Anticoagulants (Blood Thinners): Jatenzo may increase the activity of medicines like warfarin, which raises the risk of bleeding. Close monitoring of the International Normalized Ratio (INR) and prothrombin time is recommended, especially when starting or stopping Jatenzo.
  • Diabetes Medications: Androgens, including Jatenzo, may change how the body responds to insulin, leading to decreased blood glucose levels. Patients with diabetes may require a reduction in the dosage of their insulin or other antidiabetic agents to prevent hypoglycemia (low blood sugar).
  • Corticosteroids: Combining Jatenzo with corticosteroids, such as prednisone, can increase the risk of fluid retention (edema). Patients with pre-existing heart, liver, or kidney disease may be at higher risk for this side effect and should be monitored for swelling.
  • Medications that Increase Blood Pressure: Jatenzo itself can raise blood pressure. Taking it concurrently with other medications that increase blood pressure, such as certain decongestants (e.g., pseudoephedrine) or some nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen, may lead to further, potentially significant, blood pressure increases.
Advertisements

Mechanism of Action

Molecular Activation and Lymphatic Delivery

Jatenzo's mechanism relies on a prodrug activation system, initiated during the digestive process. The molecule is absorbed into the lymphatic system via the body's fat-transport mechanism, thus avoiding initial hepatic metabolism. Once in the systemic circulation, esterase enzymes perform hydrolysis to cleave the ester bond, converting the inactive testosterone undecanoate into active testosterone.

Intracellular Receptor Binding and Gene Regulation

The active testosterone acts as an agonist for the Androgen Receptor (AR), a protein found inside various cells. The bound receptor-ligand complex moves to the cell nucleus, where it modulates gene activity (transcription). This process is integral to the modulation of gene activity that directs anabolic pathways and influences protein turnover.

Endocrine Feedback and Systemic Modulation

The resulting increase in circulating testosterone initiates a negative feedback signal within the Hypothalamic-Pituitary-Gonadal (HPG) axis. This action reduces the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), resulting in decreased synthesis of endogenous testosterone. This determines the overall circulating concentration of the active hormone primarily through the external source.

Advertisements

Dosage and Administration Information

How Jatenzo is Used: Administration Guidelines

Jatenzo (testosterone undecanoate) is used as a liquid-filled oral capsule for long-term testosterone maintenance therapy in adult males. The administration process follows a specific route, schedule, and monitoring protocol to ensure proper absorption and effectiveness.


Dosing and Administration Schedule

Administration Scope Guidance
Route of Administration Oral administration (swallowed capsule).
Dosing Schedule The standard starting dose is 237 mg twice daily (BID). Dosage is individualized, with a maintenance range that may vary, but the maximum recommended dose is 396 mg twice daily.
Timing in Relation to Meals The capsule must be taken with food to ensure appropriate absorption.
Physical Handling Capsules must be swallowed whole; they are not intended to be crushed, chewed, or split.

Procedural Context and Monitoring

Administration of Jatenzo is established as a chronic, maintenance treatment. The protocol involves administering the same dose in both the morning and the evening. For the purpose of dosage adjustment, the serum testosterone concentration is required to be measured seven days after starting the medicine or after any dose change.

Crucially, the blood sample for monitoring must be taken 6 hours after the morning dose to assess if the medicine is sustaining the appropriate hormonal levels. If a dose is missed, take the next dose at the next regularly scheduled time. The medication is not intended for use in pediatric patients.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies for Jatenzo

Evidence for Use in Hypogonadism

The research base was evaluated in studies that examined the medicine's use for Testosterone Replacement Therapy (TRT) in adult men with documented hypogonadism. The evidence was evaluated in a series of clinical trials, primarily utilizing pivotal Phase 3 studies. These trials were conducted and were monitored carefully, often using an approved topical testosterone product as a comparator, over defined time intervals.

The central research question was studied for how the formulation was observed in creating and sustaining stable hormone concentration patterns in the blood. The primary research focus was evaluated in a pharmacokinetic (PK) endpoint, which tracked the average serum testosterone concentration (Cavg). Studies report patterns observed in the studies where a significant majority of participants had serum testosterone concentrations that fell within the specific regulatory-defined target range during the core treatment period.

Outcomes Measured in Primary Efficacy Trials

This subsection was evaluated in trials using standardized scales and blood measures. Beyond the main hormone target, researchers also monitored the maximum peak testosterone concentration (Cmax) to understand the frequency of hormone concentration exceeding the upper limit of the target range. Secondary outcomes related to specific systemic measures were evaluated in studies by tracking changes in various blood biomarkers, such as hematocrit and lipid profiles. Additionally, patient-reported outcomes describing perceived discomfort and overall satisfaction were explored using specialized questionnaires, which contribute to the broader evidence landscape regarding how individuals reported their experience.

Long-Term Studies and Follow-up

The initial core research that established the primary hormonal findings was evaluated in studies with follow-up durations that were limited to approximately four months. For periods beyond this initial assessment, long-term open-label extension studies were conducted and explored the consistency of hormonal concentration patterns for up to one year and, in some cases, up to two years.

Research explored how the hormonal levels were sustained over these intermediate-to-long periods. However, the research depth is limited for long-term outcomes related to patient-reported physical measures, as the primary focus in these extension phases was observed in monitoring hormone concentration and ongoing regulatory data gathering.

Evidence in Specific Patient Groups

The research was evaluated in specific patient groups that was observed in the general hypogonadism population. The studies describe patterns related to adult men, and a high proportion of the participants were included who were classified as overweight or obese. The results apply only to the populations studied who had specific forms of hypogonadism.

The trials were conducted on men with structural or genetic causes of hypogonadism, which reflects the specific population studied. The evidence base was not established through research for men whose low testosterone was observed in some studies to be attributed solely to the aging process. Similarly, this medicine was not studied for use in males younger than 18 years of age.

Research Gaps and Areas of Uncertainty

The evidence highlights what is known — and what is still uncertain — about this treatment. Regulatory bodies often identify research gaps, and the studies for this medication are no exception. One major research limitation is that the primary efficacy data was evaluated in trials with relatively short-term observation periods, meaning follow-up durations were limited.

Furthermore, long-term effects are not fully established concerning the medication's overall profile. The clinical development trials did not include research specifically designed for the purpose of assessing long-term major adverse cardiovascular outcomes (MACE). This gap necessitates ongoing post-marketing studies required by the regulator, and this research is still emerging and will contribute to the broader evidence landscape regarding long-term use patterns.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Jatenzo (FAQ)


Q: Are there specific food or drink types that must be avoided while using this medicine?

Official guidance indicates that Jatenzo must be taken with food to ensure the medicine is properly absorbed by the body. The regulatory documents do not specify any particular types of food or drink that are prohibited while using this medicine. Official information does note that there are no known specific food or alcohol interactions based on current studies.


Q: What common over-the-counter supplements or medications might interact with Jatenzo?

According to the official product information, Jatenzo may interact with several types of medicines. These include blood thinners (anticoagulants), antidiabetic agents (which may require dose adjustment), and corticosteroids (which can increase the risk of fluid retention). Additionally, certain over-the-counter drugs like nonsteroidal anti-inflammatory drugs (NSAIDs) and some decongestants may lead to further increases in blood pressure when combined with Jatenzo.


Q: How often is the blood monitoring required when taking Jatenzo?

Official information requires that blood hormone levels be measured about seven days after starting the medicine or after any dose change. Once the dose is stable, regulatory guidelines generally recommend that a healthcare provider conduct periodic monitoring for blood testosterone, hematocrit (red blood cell count), and prostate-specific antigen (PSA) levels, often periodically (e.g., every 6 to 12 months).


Q: Does using Jatenzo impact liver function?

The official safety documentation lists 'Hepatic Adverse Events' (problems with the liver) as a potential serious risk. The drug’s formulation is described as designed to avoid the extensive initial processing by the liver. Nevertheless, regulatory documents recommend that liver function tests be monitored periodically during the course of treatment.


Q: Is Jatenzo safe for someone with high blood pressure?

Jatenzo has a Boxed Warning regarding the risk of high blood pressure. Because of this, the medicine is not recommended for men who have uncontrolled hypertension (high blood pressure). Official guidance requires that a patient’s blood pressure be adequately controlled before starting treatment and that it continues to be monitored and managed while using the medicine.


Q: What are the signs that Jatenzo might not be agreeing with someone?

Official safety information reports common side effects such as headache, diarrhea, and high blood pressure, which may be signs that the medicine is not agreeing with the patient. More serious risks to watch for include sudden or severe headache, blurred vision, or signs of a blood clot such as pain or swelling in the leg or sudden chest pain. These concerns are typically addressed by a healthcare provider.


Q: Are the side effects of Jatenzo temporary, or do some last a long time?

Regulatory documents describe side effects based on clinical trial data without giving a set duration for most. However, certain serious risks, such as high blood pressure and an increase in red blood cell count (polycythemia), are conditions that are managed and monitored throughout the entire course of therapy, indicating they can persist while the patient is on the medicine.


Q: How quickly do people typically notice any effects from Jatenzo?

The official information for Jatenzo primarily focuses on how the medicine affects hormone levels in the blood. Studies indicate that a stable, consistent level of testosterone in the blood is typically achieved from about Day 7 after starting a consistent dose. The time it takes for a patient to subjectively notice symptom improvement or physical changes is not specifically defined in the official labeling.


Q: What happens if a dose is missed?

If a dose is missed, official regulatory instructions state that the user should simply take the next dose at the next regularly scheduled time. Official instructions state the user should not take extra medicine or a double dose to make up for the missed one.


Q: Are there any long-term effects of using Jatenzo that are being studied?

The initial research that led to approval had a limited observation period. Regulatory bodies require ongoing long-term open-label extension studies to track the consistency of hormonal concentration patterns over several years. Furthermore, the official documents highlight a need for and include ongoing post-marketing surveillance to assess long-term major cardiovascular outcomes (MACE) and other serious risks.


Q: Is Jatenzo used for performance enhancement by athletes?

Jatenzo is only indicated for the specific treatment of men with a documented testosterone deficiency due to a specific medical condition. Official labeling notes that testosterone products have been subject to abuse, sometimes at doses higher than prescribed, for non-medical purposes such as performance enhancement. The medicine is only indicated for specific medical use.


Q: Does Jatenzo cause changes in sleep patterns?

Official documentation lists Sleep Apnea—a condition where breathing stops or starts repeatedly during sleep—as a potential adverse reaction or a pre-existing condition that should be monitored. Additionally, general trouble sleeping (insomnia) has been reported as a less common side effect in official documents.


Q: Are there specific vision changes that have been reported with Jatenzo?

Official documentation mentions that vision changes are a possibility. Blurred vision can be a symptom associated with the serious risk of high blood pressure that is documented for Jatenzo. It is also listed as a symptom that may be experienced in the event of an overdose.


Q: Is there a maximum amount of time someone is approved to take Jatenzo?

Jatenzo is established as a chronic, maintenance treatment intended for long-term use in appropriate patients with testosterone deficiency. Regulatory documents discuss long-term open-label extension studies that have tracked use for up to one to two years, but they do not specify a maximum duration for the entire course of therapy.


Q: What kind of medical professional usually prescribes Jatenzo?

Jatenzo is a prescription-only medicine classified as a controlled substance. It requires a prescription from a licensed healthcare provider, such as a doctor or other prescribing professional. This professional typically specializes in the diagnosis and management of the specific medical forms of male hypogonadism for which the medicine is approved.


Q: Is Jatenzo available as a generic medicine?

Official drug availability records currently indicate that an FDA-approved generic version of Jatenzo is not available in the United States. The medicine is currently sold as a specific brand-name formulation.


Q: Do lifestyle factors like smoking or alcohol use affect Jatenzo?

While regulatory labeling may not detail every lifestyle factor, a history of abuse of alcohol or any drug substance can be a factor for exclusion in clinical studies. Its classification as a controlled substance highlights a potential risk of misuse, which may be heightened by certain lifestyle choices.


Q: What is the risk of dependence or misuse with Jatenzo?

Jatenzo is classified by the government as a Schedule III controlled substance. This classification indicates that the medicine carries a risk of misuse, dependency, and potential addiction. Official documentation notes that this risk is higher when the medicine is taken at doses higher than prescribed.


Q: Is Jatenzo a short-term or long-term treatment option?

The official product information states that Jatenzo is intended for use as a long-term, chronic maintenance therapy. It is used to replace testosterone indefinitely in adult males who meet the specified diagnostic requirements for deficiency.


Q: Are there patient assistance programs available for Jatenzo?

While this information is not part of the core FDA labeling, the manufacturer’s official patient support documents indicate the availability of a Copay Card for eligible patients with commercial insurance. This program is intended to help reduce the amount patients pay out-of-pocket for their prescription.


Q: What should be done if someone accidentally takes too much Jatenzo?

The official documentation describes certain signs associated with an overdose, such as a severe headache, blurred vision, or slurred speech. If an overdose is suspected, the regulatory guidance is to seek immediate medical assistance. Treatment in such a situation would consist of general supportive care.

Advertisements

How should Jatenzo be stored and disposed of?

How to Store and Dispose of Jatenzo?

This section outlines the official, regulatory requirements for storing and disposing of Jatenzo (testosterone undecanoate oral capsules).

Storage and Handling Requirement Official Mandate
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Environment Keep the capsules in a dry place and protect them from moisture to preserve product integrity.
Child Safety Must be kept out of the sight and reach of children and secured in a safe place due to its classification as a Schedule III controlled substance.
Disposal Disposal of unused or expired medicine is strongly recommended through an official drug take-back program (e.g., pharmacy collection or DEA event).

The official storage profile mandates maintaining a controlled temperature and avoiding moisture to ensure stability. The drug's classification as a controlled substance requires it to be stored securely and out of the reach of children. The recommended disposal method prioritizes specialized take-back programs to prevent misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Jatenzo found in:

A-Z Index: